Phaseline

Targets › CD24

CD24 (Signal transducer CD24): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Aug 2027.

May have a pivotal role in cell differentiation of different cell types. Signaling could be triggered by the binding of a lectin-like ligand to the CD24 carbohydrates, and transduced by the release of second messengers derived from the GPI-anchor. (UniProt, P25063)

Open in Phaseline: the race on CD24, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
OncoC4ONC-783
Bispecific antibody targeting CD24 and CD3
CD24, CD3Phase 1Advanced Solid TumorAug 2027
Pheast TherapeuticsPHST001
anti-CD24 macrophage checkpoint inhibitor
CD24Phase 1Advanced Solid TumorsApr 2029

Conditions

Advanced Solid Tumor (1) Advanced Solid Tumors (1)

Modalities

antibody (1), mixed (1)

Companies

OncoC4 (1) Pheast Therapeutics (1)

Related targets

CD3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.